Synergy Pharmaceuticals Inc. (NASDAQ:SGYP) is now up 59.57% compared to a 12-month low of $0.07. We have seen the price to move 34.9% higher and get settled at $0.11 on 12/28/2018. At recent session, it appeared stuck in a range of $0.08 to $0.1177. This company shares are 1718.18% off its target price of $2 and the current market capitalization stands at $31.28M. The recent change has given its price a -77.51% deficit over SMA 50 and -96.01% deficit over its 52-week high. The stock witnessed -69.89% declines, -93.43% declines and -93.47% declines for the 1-month, 3-month and 6-month period, respectively. To measure price-variation, we found SGYP’s volatility during a week at 25.3% and during a month it has been found around 23.62%.Synergy Pharmaceuticals Inc. (SGYP) Top Holders
Institutional investors currently hold around $11 million or 38.6% in SGYP stock. Look at its top three institutional owners. Blackrock Inc. owns $2.5 million in Synergy Pharmaceuticals Inc., which represents roughly 7.99% of the company’s market cap and approximately 22.71% of the institutional ownership. Similar statistics are true for the second largest owner, Vanguard Group Inc, which owns 22,025,593 shares of the stock are valued at $2.47 million. The third largest holder is State Street Corp, which currently holds $1.28 million worth of this stock and that ownership represents nearly 4.1% of its market capitalization.
At the end of September reporting period, 48 institutional holders increased their position in Synergy Pharmaceuticals Inc. (NASDAQ:SGYP) by some 6,458,659 shares, 58 decreased positions by 7,693,336 and 47 held positions by 82,243,645. That puts total institutional holdings at 96,395,640 shares, according to SEC filings. The stock grabbed 18 new institutional investments totaling 1,607,306 shares while 20 institutional investors sold out their entire positions totaling 1,147,782 shares.Synergy Pharmaceuticals Inc. (NASDAQ:SGYP) Insider Trades
Multiple company employees have indulged in significant insider trading. Synergy Pharmaceuticals Inc. disclosed in a document filed with the US Securities and Exchange Commission (SEC) that 10% Owner Paulson & Co. Inc. has sold 8,750,000 shares of Synergy Pharmaceuticals Inc. (SGYP) in trading session dated Nov. 10, 2017. These shares are worth $24,675,000 and were traded at $2.82 each. The SEC filing shows that Paulson & Co. Inc. performed a sale of 26,287 shares. The 10% Owner disposed these shares by way of transaction on Aug. 07, 2017. The company’s shares were given away at $3.77 per share worth to an income of some $99,102 on account of Paulson & Co. Inc..
CEO, Jacob Gary S, purchased 5,680 common shares of Synergy Pharmaceuticals Inc. (SGYP) in the open market. In a transaction dated May. 26, 2017, the shares were bought at an average price of $3.52, giving away a sum of $19,994. After this purchase, 402,679 common shares of SGYP are directly owned by the insider, with total stake valued at $44,295.
In the transaction dated May. 26, 2017, the great number of shares acquired came courtesy the Director; Brancaccio John P added a total of 6,500 shares at an average price of $3.59, amounting to approximately $23,335. The insider now directly owns 30,444 shares worth $3,349.
Several analysts have released their opinion on Synergy Pharmaceuticals Inc. (NASDAQ:SGYP), with 0 analysts believing it is a strong buy. Whereas 2 of them predict the stock is a hold. Also, there are 1 buy, 0 sell and 0 strong sell ratings, collectively assigning a 2.67 average brokerage recommendation.